AbbVie Ready To Leverage Migraine Franchise In Crowded Market

Qulipta Adds Indication Not Covered By Botox, Ubrelvy

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

The US FDA approved the oral CGRP inhibitor Qulipta (atogepant) for migraine prevention, making AbbVie the only company with three drugs for three different migraine indications.

Woman suffers migraine while standing in a crowd of people
AbbVie brings seventh CGRP inhibitor to crowded migraine market • Source: Alamy

AbbVie Inc. has expanded its migraine franchise to three drugs with three different indications with the US Food and Drug Administration approval of its second CGRP inhibitor Qulipta (atogepant). It remains to be seen whether the triple-drug offering will provide a competitive advantage in the increasingly crowded anti-CGRP space, but the big pharma is expected to use its relatively long-term presence in the migraine market to its advantage.

AbbVie established itself as a player in the space through its $63bn acquisition of Allergan plc in 2019, gaining...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

Scrip-NewProducts (Premium-2): Top 12 Pharma Companies: Pfizer Tops The Leaderboard Again

 
• By Nabil

The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.

Innovent/GenFleet Score China’s First KRAS G12C Inhibitor Approval

 
• By Dexter Jie Yan

The nod will help unlock a national market for the partners’ Dupert (fulzerasib) in which roughly 50,000 people are expected to be newly diagnosed with lung cancer harboring the KRAS G12C mutation in 2025. Meanwhile, two other homegrown rivals are also closing in on marketing clearances in China.

Cagrisema Leads The Charge For 2025

 
• By Elizabeth Cairns

2030 sales forecasts for Novo’s obesity hope are an order of magnitude larger than its closest rival among 2025’s expected debutantes.  

Small But Mitey: Tarsus To Amp Up Strong Xdemvy Launch

 
• By Alexandra Shimmings

Tarsus Pharmaceuticals is putting more sales and marketing heft behind its novel eyelid disease therapy, Xdemvy, to capitalize on a solid start in a previously untapped market.    

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.